CN107569507A - A kind of active ingredient of Chinese herbs composition and application thereof - Google Patents
A kind of active ingredient of Chinese herbs composition and application thereof Download PDFInfo
- Publication number
- CN107569507A CN107569507A CN201710798253.1A CN201710798253A CN107569507A CN 107569507 A CN107569507 A CN 107569507A CN 201710798253 A CN201710798253 A CN 201710798253A CN 107569507 A CN107569507 A CN 107569507A
- Authority
- CN
- China
- Prior art keywords
- ginsenoside
- parts
- active ingredient
- ophiopogonin
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention relates to a kind of active ingredient of Chinese herbs composition and application thereof, the pharmaceutical composition being specifically prepared by compound ginsenoside Rg1, ginsenoside Rb1, ginsenoside Re and ophiopogonin D according to constant weight number proportioning.The pharmaceutical composition of the present invention shields in cardiac muscle cell's oxidative damage to cardiac muscle cell, and with effects such as promotion angiogenesis, the treatment available for cardiovascular and cerebrovascular disease.
Description
Technical field
The present invention relates to pharmaceutical technology field, and in particular to a kind of active ingredient of Chinese herbs composition, specifically in
Medicine active component ginsenoside Rg1, ginsenoside Rb1, ginsenoside Re and ophiopogonin D are matched according to constant weight number and made
The standby pharmaceutical composition formed and its purposes in the medicine for treating and preventing cardiovascular and cerebrovascular disease is prepared.
Background technology
In recent years, because the event for drug resistance and toxic side effect occur and being recalled by the whole world is constantly sent out after chemicals listing
It is raw, screened with lead compound, structural modification transform the New Drug Research technological deficiency of core as and increasingly burst, with single target spot
Facedown treatment receives serious challenge for the new drug development pattern of representative, and the reasonability of polypharmacy principle is gradually the world
Society is received, and traditional Chinese medicine compound preparation is led due to complicated component, medicinal material individual difference and each producer preparation technology difference
Active constituent content in the preparation of different batches, ratio difference are caused, pharmacodynamic stability is not high, simultaneously because other uncertain compositions
Presence, cause side effect to increase, adverse reaction rate rise.Found from classical effectively Chinese medicine compound prescription with certain effect
" functional component group ", and by the proportioning combination of certain compatibility, composition is clear for exploitation, quality controllable, clear mechanism, safely and effectively existing
For Chinese medicine, new thinking is provided for the exploitation of modern compound medicine.
Angiocardiopathy is to seriously endanger a kind of disease of human health.The World Health Organization（WHO）As shown by data, the whole world are dead
Account for the 1/3 of a variety of causes death toll in cardiopathic people, with aging population and people's dietary structure change etc. it is many because
Element, its incidence and mortality just rise year by year, and morbidity crowd also tends to rejuvenation, complicated yet with its pathogenesis,
Not yet illustrate completely at present, the theory such as oxygen free radical injury, cardiac muscle cell apoptosis, endothelial cell damage, intracellular calcium overload.But
It is to take to obtain remedy measures and medicine the effect of can not obtaining ideal for developing according to these theories, some is even produced
Raw more serious adverse reaction.So far, the active drug of very good treatment angiocardiopathy, exploitation treatment be there is no
The medicine of angiocardiopathy is as raising level of human health and life quality important topic urgently to be resolved hurrily.In early-stage Study
In, we are studied for cardiovascular and cerebrovascular disease by classical pharmacology, metabolism group, genomics and molecular pharmacology etc.
Repeated screening is verified, has obtained being combined by the effective ingredient in Chinese that ginseng extract and ophiopogon japonicus extract form, and has been applied specially
Profit, application number CN201410314535.6.Meanwhile component is clear and definite, quality controllable, clear mechanism, safely and effectively modern Chinese herbal medicine,
It is the target that pharmacy worker pursues during Chinese medicine compound prescription new drug is developed, therefore, in screening ginseng extract, tuber of dwarf lilyturf extraction
On the basis of the optimum proportioning of thing treatment cardiovascular and cerebrovascular disease, inventor further screens its active chemical and its optimal compatibility
Ratio, experiment basis are established for exploitation definite ingredients, quality controllable modern Chinese herbal medicine compound preparation.Present invention research ginsenoside
Rg1, ginsenoside Rb1, ginsenoside Re and ophiopogonin D compatibility anti-myocardial oxidative damage, promote angiogenesis and
Good effect is shown in cerebral ischemia re-pouring injured.
The content of the invention
Studies have found that the pathological conditions of animal angiocardiopathy model and cardiovascular patient crowd can cause cardiac muscle cell
Generation apoptosis.And most cardiac muscle cell apoptosis paths all with active oxygen（ROS）It is closely related.Therefore it is anti-oxidant to improve cardiac muscle cell
Radical damage ability is the key of prevention and cure of cardiovascular disease.H2O2 is the product of vivo oxidation metabolism, while is a kind of weight again
The active oxygen wanted, cell can easily be caused damage to a certain extent through cell membrane, intracellular H2O2 accumulation.Exogenous H2O2 makees
During for cardiac muscle cell, H2O2 enters into the cell through cell membrane, is directly becoming intracellular ROS, and activating transcription factor core
Factor κ B, up-regulation promote expression of apoptotic gene, and apoptosis occurs for inducing cardiomyocytes.
The invention discloses one kind by ginsenoside Rg1, ginsenoside Rb1, ginsenoside Re and ophiopogonin D as activity into
The active ingredient of Chinese herbs composition divided.Different combination of active principles has multicomponent, multipath, stable anti-myocardial oxygen
Change damage, promote the action character of angiogenesis and anti-cerebral ischemia reperfusion injury.The active ingredient of Chinese herbs composition of the present invention
Curative effect is high, and definite ingredients are quality controllable, can effectively treat and prevent cardiovascular and cerebrovascular disease.
The partial function components group of ginseng and the tuber of dwarf lilyturf is combined into a compound medicament composition by the present invention, is being prepared into preparation
When, functional component group gross weight used in the present invention is total well below ginseng and the active component of tuber of dwarf lilyturf decocting liquid or extract combination
Weight, this provides great convenience to being prepared into formulation application, especially when preparing liquid preparation, is advantageous to the molten of medicine
Solution, impurity content are reduced, and clarity improves, and medicine is safe and stable controllable；Be advantageous to illustrating for mechanism of drug action simultaneously.And
And inventor confirms that this functional component group compound passes through multicomponent integration or collaboration by the drug efficacy study of different levels
Mechanisms play improves multifactor caused cardiac muscle cell's oxidative damage, endothelial cell damage, myocardial ischemia etc., is ensureing curative effect
On the basis of, medication dose is reduced, is advantageous to be made modern formulation, modern herbal mixture with active principle/components compatibility.
The pharmaceutical composition of the present invention includes active ingredient of Chinese herbs ginsenoside Rg1, ginsenoside Rb1, ginsenoside Re and Mai
Winter saponin D, is counted in parts by weight, the compound ginsenoside Rg1, ginsenoside Rb1, ginsenoside Re and ophiopogonin D
Ratio of weight and number it is preferred：1 ~ 40 part of ginsenoside Rg1,1 ~ 20 part of ginsenoside Re, 1 ~ 40 part of ginsenoside Rb1, the tuber of dwarf lilyturf
1 ~ 10 part of saponin D.The ratio of weight and number of further preferred four compounds is：35 ~ 40 parts of ginsenoside Rg1, ginsenoside
18 ~ 20 parts of Re, 35 ~ 40 parts of ginsenoside Rb1,1 ~ 2 part of ophiopogonin D.The parts by weight of further preferred four compounds
Than for：1 ~ 5 part of ginsenoside Rg1,1 ~ 5 part of ginsenoside Re, 1 ~ 5 part of ginsenoside Rb1,8 ~ 10 parts of ophiopogonin D.
In a kind of preferable technical scheme, the ratio of weight and number of four compounds is：20 parts of ginsenoside Rg1, ginsenoside
20 parts of Re, 9 parts of ginsenoside Rb1,1 part of ophiopogonin D.
In a kind of preferable technical scheme, the ratio of weight and number of four compounds is：1 part of ginsenoside Rg1, ginsenoside
1 part of Re, 1 part of ginsenoside Rb1,1 part of ophiopogonin D.
In a kind of preferable technical scheme, the ratio of weight and number of four compounds is：20 parts of ginsenoside Rg1, ginsenoside
20 parts of Re, 10 parts of ginsenoside Rb1,5 parts of ophiopogonin D.
The active ingredient of Chinese herbs composition of the present invention when needed, by adding the inert excipients commonly used in pharmacy, such as dilutes
Agent, excipient, filler, adhesive, wetting agent, disintegrant, sorbefacient, surfactant, absorption carrier or lubricant
Deng can also add flavouring such as flavouring agent, sweetener etc., tablet, granule, capsule, pill, Orally disintegrating is made
Piece, oral liquid, injection, infusion solution, aerosol or inhalant etc..
It is a further object to provide the active ingredient of Chinese herbs composition to prepare treatment and prevention cardiovascular and cerebrovascular disease
Medicine in purposes.Wherein described cardiovascular and cerebrovascular disease include cerebral infarction, cerebral ischemia, coronary heart diseases and angina pectoris, myocardial ischemia,
Myocardial infarction, heart failure or arrhythmia cordis.
Raw material ginsenoside Rg1 in the present invention, ginsenoside Rb1, ginsenoside Re and ophiopogonin D are commercially available supply.
Active ingredient of Chinese herbs composition provided by the invention, there is advantages below：Effective substance is clear and definite：By ginsenoside
Rg1, ginsenoside Rb1, ginsenoside Re and ophiopogonin D compatibility, its structure is clear and definite, and component fixed mass is controllable, is this hair
Security, the validity of the clinical practice of bright composition lay the foundation；Clear mechanism：Using classical pharmacology and molecule medicine
The mode that of science and systems biology research is combined, confirms that it can maintain cardiac muscle cell's nuclear morphology by pharmacodynamic study, protects
Lysosome and mitochondria in shield heart myocyte, so as to have protective effect to the myocardial cell injury caused by hydrogen peroxide；
Cell proliferation of human umbilical vein, migration can be promoted and promote the generation of endothelial cell tubule；And make with stronger neuroprotection
With.
Brief description of the drawings:
The ginsenoside Rg1 of Fig. 1 different weights proportioning, ginsenoside Rb1, ginsenoside Re and ophiopogonin D are to oxidative damage
The influence of cardiac muscle cell's nuclear morphology；
The ginsenoside Rg1 of Fig. 2 different weights proportioning, ginsenoside Rb1, ginsenoside Re and ophiopogonin D are to oxidative damage
The influence of cardiac muscle cell's mitochondrial transmembrane potentials；
The ginsenoside Rg1 of Fig. 3 different weights proportioning, ginsenoside Rb1, ginsenoside Re and ophiopogonin D are to oxidative damage
The influence of cardiac muscle cell's lysosome.The #p compared with control group<0.01；The * compared with model group<0.05, * *<0.01；
Fig. 4 breeds to external HUVECs, migrates and the influence of angiogenesis.It is straight after 24 hours that A is that medicine acts on endothelial cell
Connect cell counts（n=6）；B is that pharmaceutical composition acts on endothelial cell MTT measurement results after 24 hours（n=6）；C is medicine
Compositions（20μg/mL）After effect 3 as a child, endothelial cell passes through the cell number of transwell cells film；D is medicine group
For HUVECs in the tubule formational situation on matrigel matrigels surface, " * " represents the group and Control after compound acts on 18 hours
Group compares P<0.05；
Composition prepared by Fig. 5 embodiments 5 peels off the influence of Reperfu- sion neurotrosis cell to oxygen sugar.Wherein, with control group phase
Compare #p<0.01；The * compared with model group<0.05, * *<0.01.
Embodiment：
The beneficial effect of composition of the present invention will be expanded on further by embodiment and combination pharmacological evaluation below
Prepare embodiment
Medicine：Ginsenoside Rg1, ginsenoside Rb1, ginsenoside Re and ophiopogonin D are purchased from the auspicious chemical industry of ancient cooking vessel（Shanghai）It is limited
Company（Purity is above 98%）；
Embodiment 1
Take ginsenoside Rg1 20mg, ginsenoside Rb1 20mg, ginsenoside Re 9mg and ophiopogonin D 1mg（Gross weight
For 50mg）, it is dissolved in the filtered pure water of 5mL, the 3 minutes mixtures that are vortexed are completely dissolved, and obtain medicine group of the present invention
Compound.
Embodiment 2
Take ginsenoside Rg1 12.5mg, ginsenoside Rb1 12.5mg, ginsenoside Re 12.5mg and ophiopogonin D
12.5mg（Gross weight is 50mg）, it is dissolved in the filtered pure water of 5mL, the 3 minutes mixtures that are vortexed are completely dissolved, and obtain this hair
Bright described pharmaceutical composition.
Embodiment 3
Take ginsenoside Rg1 10mg, ginsenoside Rb1 10mg, ginsenoside Re 10mg and ophiopogonin D 20mg（Gross weight
Measure as 50mg）, it is dissolved in the filtered pure water of 5mL, the 3 minutes mixtures that are vortexed are completely dissolved, and obtain medicine of the present invention
Compositions.
Embodiment 4
Take ginsenoside Rg1 16mg, ginsenoside Rb1 16mg, ginsenoside Re 16mg and ophiopogonin D 2mg（Gross weight
For 50mg）, it is dissolved in the filtered pure water of 5mL, the 3 minutes mixtures that are vortexed are completely dissolved, and obtain medicine of the present invention
Composition.
Embodiment 5
Take ginsenoside Rg1 20g, ginsenoside Rb1 20g, ginsenoside Re 10g and ophiopogonin D 5g（Gross weight is
55g）Mix, then addition starch, microcrystalline cellulose, talcum powder, 5% starch slurry are appropriate, mix, particle is made.
Embodiment 6
Take ginsenoside Rg1 38mg, ginsenoside Rb1 19mg, ginsenoside Re 36mg and ophiopogonin D 2mg（Gross weight
For 95mg）Mix, be dissolved in the filtered pure water of 10mL, the 3 minutes mixtures that are vortexed are completely dissolved, and are obtained of the present invention
Pharmaceutical composition.
Embodiment 7
Take ginsenoside Rg1 4g, ginsenoside Rb1 4g, ginsenoside Re 4g and ophiopogonin D 8g（Gross weight is 20g）
Mix, addition starch, microcrystalline cellulose, talcum powder, 5% starch slurry are appropriate, mix, particle is made.
Pharmacological experiment and result
1. using cardiac muscle cell H2O2Model of oxidative is investigated protection of the present composition to oxidative damage cardiac muscle cell and made
With.
1.1 method[1]
1.1.1 separation, purifying and the original cuiture of rat myocardial cell take 2 ~ 3d SD rats 10, and 75% ethanol eliminates chest
Preceding skin, Sterile ophthalmic, which is cut, cuts off thoracic cavity, is taken out heart with ophthalmic tweezers, be put into rapidly precooling without Ca2+, Mg2+
In PBS, rinse 3 times repeatedly, and remove the blood clot and fibr tissue of heart surface, be cut into 1mm3The fragment of size, adds
Enter 0.125% pancreatin of 5 times of volumes and the digestive juice of 0.05% clostridiopetidase A, 37Digestion is vibrated in water-bath, is abandoned after digesting 5min
Clearly.Digestion 3 times is repeated, 8min/ times, postdigestive supernatant every time is collected, adds appropriate（It is isometric with supernatant）Containing 10% tire ox
The RMPI-1640 culture mediums of serum.Terminate the effect of digestive ferment.The cell suspension of each digestion is collected in 10mL centrifuge tubes, 41000rpm, 9min is centrifuged, abandon supernatant, collect the cell precipitation of centrifuge tube lower end, add the hyclone culture mediums of 8mL 15%
Fully single cell suspension is slowly filtered into single cell suspension, is inoculated in blake bottle and is placed in CO by piping and druming through screen cloth2Incubator
（37CO2, 95% air）It is interior, not yet adherent cell suspension is suctioned out after 90min, cell density is adjusted after cell count
And 96 orifice plates are inoculated in, until cell is used for subsequent experimental after growing up to fine and close individual layer.
1.1.2MTT the influence of method measure different pharmaceutical concentration versus cell activity.Methyl tetrazolium blue（MTT）Colorimetric test is a kind of
The method for detecting cell survival and growth.Cell density is adjusted to 3105Individual/mL, 100 μ L add 96 orifice plates per hole, until
Cell is used to test after growing up to fine and close individual layer.Add positive drug（Shenmai injection, 400,2000,4000,8000mg/L）, through this
Invention medicine（Embodiment 1 ~ 4,8,40,80,160 mg/L）With through medicine of the present invention（The mg/ of embodiment 5,10,50,100,200
L）The μ L of pharmaceutical culture medium 100, blank control group add isometric culture medium, are inhaled after incubation 24h and abandon nutrient solution.10 μ are added per hole
LMTT solution（5 mg/mL, i.e. 0.5% MTT）In 100 μ LRMPI-1640 culture mediums, inhaled after continuing culture 4 hours and abandon liquid,
Add the μ L/ holes of DMSO 100, be stored at room temperature 10min, with the OD values at 96 hole ELIASA Detection wavelength 490nm.Take every group of OD values
Average, the inhibiting rate of cell proliferation is calculated by formula.Inhibiting rate（%）=（1- administration groups OD values/blank control group OD values）
100%, 5 multiple holes are set.
1.1.3 the drug dose that medicine packet and the foundation of cellular damage model determine according to MTT testing results is grouped：Control group（Control）：Cardiac muscle cell is without any processing, by normal condition culture；Model group（Model）；It is positive
The high, medium and low dosage group of medicine Shenmai injection（400、2000、4000 mg/L）；1 high, medium and low dosage group of embodiment（8、40、
80 mg/L）；2 high, medium and low dosage group of embodiment（8、40、80 mg/L）；3 high, medium and low dosage group of embodiment（8、40、
80 mg/L）；4 high, medium and low dosage group of embodiment（8、40、80 mg/L）；5 high, medium and low dosage group of embodiment（10、
50、100 mg/L）.Above each group n=4.Medicament protection group is with H2O2Before inducing cardiomyocytes damage, above-mentioned dosage is previously added
Each group drug incubation 24 hours.Pastille culture medium is sucked, adds 100 μm of ol/L H2O2Solution, it is small that 2 are incubated into incubator
Shi Hou, make cellular damage model.
1.1.4 multi-parameter Apoptosis detects relevant for detectable three kinds of the multi-parameter apoptosis kit of High content screening
The basic parameter of Apoptosis：Sour environment and proton capture ability in nuclear morphology, mitochondrial transmembrane potentials and lysosome
Change.Detection karyomorphism change passes through nucleus dye Hoechst 33342 staining cell core.Detect mitochondria
Membrane potential passes through the mitochondria in fluorescent dye Mito Tracker Red staining cells.Detect lysosome sour environment and
Proton capture ability passes through the lysosome in fluorescent dye LysoTracker Red staining cells.The cell of 96 orifice plates is dyed
After fixation, every hole cell is detected in the fluoroscopic image of respective excitation wavelength passage by ArrayScan HCS system and made
Image is analyzed with vHCS6.2 software collections.
1.2 experimental result
1.2.1 influence of the composition that prepared by embodiment 1 ~ 5 to damaged myocardium karyomorphism
Hoechst can pass through the complete cell of after birth, and being combined with double-stranded DNA makes core in blueness.Nucleus DNA piece in apoptotic process
Disconnectedization is in fragment dispersed fabric.H of the cardiac muscle cell through 100 μm of ol/L2O2After damage, nuclear morphology becomes big, poor with normal group
It is different notable（P<0.01）；Shenmai injection（Positive drug）, the present invention in pharmaceutical composition（Embodiment 1 ~ 5）High, medium and low dosage
Pre- protection can significantly resist H2O2The nuclear morphology of cardiac muscle cell is damaged（P<0.01）, as shown in Figure 1.
The #p compared with control group<0.01；The * compared with model group<0.05, * *<0.01.
1.2.2 influence of the composition that prepared by embodiment 1 ~ 5 to damaged myocardium cell mitochondrial membrane potential
H of the cardiac muscle cell through 100 μm of ol/L2O2After damage, mitochondrial transmembrane potentials reduce, notable with normal group comparing difference（P
<0.01）；Shenmai injection（Positive drug）, the present invention in pharmaceutical composition（Embodiment 1 ~ 5）High, medium and low dosage group can show
The decline for suppressing cardiomyocyte transmembrane current potential is write, compared with model group, its fluorescence intensity ratio is significantly raised（P<0.01）, such as scheme
Shown in 2.
The #p compared with control group<0.01；The * compared with model group<0.05, * *<0.01.
1.2.3 the influence of 1 ~ 5 pair of damaged myocardium Cytolysosome of embodiment
H of the cardiac muscle cell through 100 μm of ol/L2O2After damage, sour environment and proton capture ability in lysosome are destroyed,
Fluorescence volume reduces, notable with normal group comparing difference（P<0.01）.；Shenmai injection（Positive drug）, the present invention in medicine group
Compound（Embodiment 1 ~ 5）High, medium and low dosage group can be significantly inhibited under sour environment and proton capture ability in lysosome
Drop, compared with model group, its fluorescence intensity ratio is significantly raised（P<0.01）, as shown in Figure 3.
Result above shows that the cardiac muscle cell of pre- protective effect, mitochondrial membrane potential is higher, and permeability of cell membrane is smaller, cell
Core is complete, and cell viability degree is higher, illustrates that the composition of the preparation of the embodiment of the present invention 1 ~ 5 has and resists H2O2Cause cardiac muscle cell
The effect of oxidative damage.
2. cell proliferation of human umbilical vein, migration and the effect experiment for promoting the generation of endothelial cell tubule
Using Human umbilical vein endothelial cells（HUVECs）Investigate composition endothelial cell proliferation, migration prepared by embodiment 4,5
And the influence of angiogenesis etc..Cell count and MTT results show（Fig. 4 A, B）, composition provided by the invention（Implement
Example 5）HUVECs can be promoted to breed；Cell migration assay result shows（Fig. 4-C）The medicine of embodiment 5 significantly increases moving for HUVECs
Shifting ability；HUVECs forms result of the test in matrigel matrigels surface tubule and shown（Fig. 4-D）, 20 μ g/mL（Embodiment 4,
5）It is obviously promoted the generation of HUVECs tubules.
3. pair oxygen sugar peels off the influence experiment of Reperfu- sion neurotrosis cell.
3.1 method
The SH-SY5Y cells frozen are taken out from liquid nitrogen, are placed in 37 rapidlyMelt in water-bath.Then cell suspension is drawn extremely
In sterile centrifugation tube, 5mL RPMI-1640 cell culture fluids are added, are centrifuged under 1000rpm.Abandoning supernatant, it is repeated twice,
Then 4mL RPMI-1640 complete mediums are added（It is dual anti-comprising 10%PBS, 1%）, make cell suspension equal with the piping and druming of washing lotion rifle
Even, it is 25cm to be then transferred to floor space2Blake bottle, in 5%CO237Cultivated in incubator.Change within average every 2 days and once train
Nutrient solution, passed on when cell confluency degree is 80-90%.Old culture medium is first discarded during passage, the pancreatin for adding 1mL0.25% disappears
Change liquid, 2min is stood in incubator.Then pancreatin digestive juice is discarded, blake bottle is washed 2 times with PBS, and it is fresh complete then to add 2mL
Full culture medium, blown and beaten with washing lotion rifle, after attached cell suspends, with 1：2 ratio is transferred to new blake bottle, supplies complete training
Nutrient solution is then placed in cell culture incubator and cultivated to 4mL.When expanding culture, with 75 cm2Blake bottle, add 12 mL training
Foster base is cultivated.
With reference to the method for building up of the OGD models of the reports such as Elke Fordel, optimized according to this experiment actual conditions.Recovery
Cell pass 3 generations after, when degree of converging reaches 80%-90%, discard nutrient solution, add 1mL0.25% pancreatin digestive juice, training
Support in case and stand 2min, then discard pancreatin digestive juice, blake bottle is washed 2 times with PBS, then adds fresh complete medium regulation
Cell density is 2105Individual/mL, after being inoculated in 96 orifice plate culture 18h per the μ L of hole 100, it will be cultivated for blank group and model group
Base changes RPMI-1640 basal mediums into, changes culture medium with diluting into RPMI-1640 basal mediums into for administration group
To decoction.After pretreatment 4 hours, the culture medium of blank control group remains as RPMI-1640 basal mediums, and administration group will cultivate
Base change into sugar-free DMEM basal mediums dilute to decoction, be put into three gas incubators, set gas concentration lwevel as 5%,
Oxygen concentration is 0.2%, and oxygen concentration is reduced by entering nitrogen.After OGD models 10 hours, while take out blank control group and OGD
Model group, change each group culture medium into RPMI-1640 basal mediums, be put into normal cell culture incubator, it is small to continue culture 24
When to simulate refilling process.Each dosage group does 3 groups of repetitions.
After OGD-R models terminate, each 96- orifice plates are taken out, culture medium are changed to 1640 basal mediums of the reagent containing 20%MTS into, so
OD values are determined under 490nm with ELIASA, during calculating, using 1640 basal mediums of not celliferous 20%MTS reagents as the back of the body afterwards
Scape value, cell viability calculation formula are as follows：Cell viability（%）=（Experimental group OD values-background OD）/（The blank control group OD values-back of the body
Scape OD） 100%。
3.2 experimental result：As shown in figure 5, the activity of the composition of the preparation of various concentrations embodiment 5 is determined using MTS methods,
As a result show, the pharmaceutical composition of the present invention of various concentrations has certain neuroprotection.
Claims (10)
1. a kind of active ingredient of Chinese herbs composition, it is characterised in that contain active ingredient of Chinese herbs ginsenoside Rg1, ginsenoside
Rb1, ginsenoside Re and ophiopogonin D and pharmaceutically acceptable carrier.
2. the effective chemical analysis composition of Chinese medicine according to claim 1, it is characterised in that the parts by weight between active component
Counting ratio is：
1 ~ 40 part of ginsenoside Rg1
1 ~ 20 part of ginsenoside Re
1 ~ 40 part of ginsenoside Rb1
1 ~ 10 part of ophiopogonin D.
3. active ingredient of Chinese herbs composition according to claim 2, it is characterised in that the ratio of weight and number between active component
For：
35 ~ 40 parts of ginsenoside Rg1
18 ~ 20 parts of ginsenoside Re
35 ~ 40 parts of ginsenoside Rb1
1 ~ 2 part of ophiopogonin D.
4. active ingredient of Chinese herbs composition according to claim 2, it is characterised in that the ratio of weight and number between active component
For：
1 ~ 5 part of ginsenoside Rg1
1 ~ 5 part of ginsenoside Re
1 ~ 5 part of ginsenoside Rb1
8 ~ 10 parts of ophiopogonin D.
5. Chinese medicine active ingredient composition according to claim 2, it is characterised in that the ratio of weight and number between active component
For：
20 parts of ginsenoside Rg1
20 parts of ginsenoside Re
9 parts of ginsenoside Rb1
1 part of ophiopogonin D.
6. Chinese medicine active ingredient composition according to claim 2, it is characterised in that the ratio of weight and number between active component
For：
1 part of ginsenoside Rg1
1 part of ginsenoside Re
1 part of ginsenoside Rb1
1 part of ophiopogonin D.
7. Chinese medicine active ingredient composition according to claim 2, it is characterised in that the ratio of weight and number between active component
For：
20 parts of ginsenoside Rg1
20 parts of ginsenoside Re
10 parts of ginsenoside Rb1
5 parts of ophiopogonin D.
8. active ingredient of Chinese herbs composition according to claim 1, it is characterised in that pharmaceutically acceptable carrier includes
One or more in disintegrant, diluent, filler, adhesive, lubricant, cosolvent.
9. according to any described active ingredient of Chinese herbs compositions of claim 1-8, it is characterised in that can be made into injection,
The formulations such as granula, freeze drying powder injection, tablet, capsule.
10. active ingredient of Chinese herbs composition according to any one of claims 1 to 9 is preparing treatment and prevention cardiovascular and cerebrovascular disease
Purposes in the medicine of disease.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710798253.1A CN107569507A (en) | 2017-09-07 | 2017-09-07 | A kind of active ingredient of Chinese herbs composition and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710798253.1A CN107569507A (en) | 2017-09-07 | 2017-09-07 | A kind of active ingredient of Chinese herbs composition and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107569507A true CN107569507A (en) | 2018-01-12 |
Family
ID=61031129
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710798253.1A Pending CN107569507A (en) | 2017-09-07 | 2017-09-07 | A kind of active ingredient of Chinese herbs composition and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107569507A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115778967A (en) * | 2022-11-15 | 2023-03-14 | 中国科学院遗传与发育生物学研究所 | Application of ginsenoside Rh2, ophiopogonin D and schisandrin B in treating myocardial injury |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103393708A (en) * | 2013-08-20 | 2013-11-20 | 大理药业股份有限公司 | Ginsenoside-ophiopogonin D composition for treating cardiovascular and cerebrovascular diseases |
-
2017
- 2017-09-07 CN CN201710798253.1A patent/CN107569507A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103393708A (en) * | 2013-08-20 | 2013-11-20 | 大理药业股份有限公司 | Ginsenoside-ophiopogonin D composition for treating cardiovascular and cerebrovascular diseases |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115778967A (en) * | 2022-11-15 | 2023-03-14 | 中国科学院遗传与发育生物学研究所 | Application of ginsenoside Rh2, ophiopogonin D and schisandrin B in treating myocardial injury |
| CN115778967B (en) * | 2022-11-15 | 2023-11-14 | 中国科学院遗传与发育生物学研究所 | Application of ginsenoside Rh2 and ophiopogonin D combined with schisandrin B in treatment of myocardial injury |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102143744B (en) | 7,8-dihydroxyflavone and derivant purposes in the medicine of preparation treatment depression thereof | |
| US7906159B2 (en) | Herbal compositions and methods for enhancing vital energy and athletic performance | |
| CN108530430B (en) | Ester type catechin pyrrolidine alkaloid and preparation method and application thereof | |
| CN103550484A (en) | Pharmaceutical composition for adjusting estrogen level as well as preparation method and application thereof | |
| CN101278939B (en) | Medicament composition for curing cardiovascular and cerebrovascular diseases and method of preparing the same | |
| CN103585400A (en) | Composition having immunity enhancing and fatigue alleviating effects, and preparation method thereof | |
| CN101744863A (en) | Persimmon leaf extract preparation, preparing method thereof and application thereof | |
| CN102233009B (en) | Chinese medicinal composition for promoting nerve regeneration and preparation method and use thereof | |
| CN107569507A (en) | A kind of active ingredient of Chinese herbs composition and application thereof | |
| CN107041924A (en) | It is a kind of prevent and treat diabetic nephropathy towards medicine compound extract and preparation method thereof | |
| CN100581552C (en) | Compound puerarin for treating cardiovascular and cerebrovascular disease | |
| JI et al. | Antihepatocarcinoma effect of solanine and its mechanisms | |
| CN110585224A (en) | Application of timosaponin BI, timosaponin IA and timosaponin AIII in preparation of medicine for treating cognitive disorder | |
| CN110403951A (en) | A kind of ophiopogonin D preparation and its blood lipid-lowering medicine new application | |
| CN105687262A (en) | Folium ginkgo tincture and preparing method thereof | |
| KR20050047579A (en) | Bone disease drug composition using herb medicines | |
| CN1788753B (en) | General glycoside extract from tree peony root bark and its preparation method and uses thereof | |
| CN101744806A (en) | Application of pinocembrin raceme in preparation of medicals for cerebral apoplexy | |
| CN106074507A (en) | Pharmaceutical composition that prevention of arterial is atherosis and application thereof | |
| CN102068520A (en) | Chinese medicinal composition for treating cardiovascular and cerebrovascular diseases and preparation method thereof | |
| CN110664826A (en) | Ophiopogon japonicus saponin D' preparation and new application of hypoglycemic drug thereof | |
| CN101879280B (en) | Composition for nourishing kidney, replenishing vital essence, promoting mentality and calming nerves, and preparation method | |
| CN110664828A (en) | Ophiopogon japonicus saponin D preparation and new application of hypoglycemic drug thereof | |
| CN104434940A (en) | Application of panax japonicus IV a in prevention and treatment of cardiovascular disease and complication of cardiovascular disease | |
| CN110051664A (en) | A kind of application of ginkgo lactone composition in drug of the preparation for acute coronary syndrome |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| TA01 | Transfer of patent application right | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20180517 Address after: 051430 No. 168, Shi Luan street, Luancheng District, Shijiazhuang, Hebei. Applicant after: China Shineway Pharmaceutical Group Co., Ltd. Applicant after: Hebei Shineway Pharmaceutical Co., Ltd. Applicant after: Beijing Tianjin Hebei LIAN pharmaceutical research (Beijing) Co., Ltd. Address before: 051430 No. 168, Shi Luan street, Luancheng District, Shijiazhuang, Hebei. Applicant before: China Shineway Pharmaceutical Group Co., Ltd. Applicant before: Hebei Shineway Pharmaceutical Co., Ltd. |
|
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20180112 |